You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 138 No. 8, August 2002 TABLE OF CONTENTS
  Archives
  •  Online Features
  Study
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (83)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Dermatologic Disorders
 •Dermatologic Disorders, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Correlations Between Clinical Patterns and Causes of Erythema Multiforme Majus, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis

Results of an International Prospective Study

Ariane Auquier-Dunant, MS; Maja Mockenhaupt, MD; Luigi Naldi, MD; Osvaldo Correia, MD; Werner Schröder, MD; Jean-Claude Roujeau, MD; for the SCAR Study Group

Arch Dermatol. 2002;138:1019-1024.

Background  It was proposed that Stevens-Johnson syndrome and toxic epidermal necrolysis differed from erythema multiforme majus by the pattern and localization of skin lesions.

Objective  To evaluate the validity of this clinical separation.

Design  Case-control study.

Settings  Active survey from 1989 to 1995 of 1800 hospital departments in Europe.

Patients  A total of 552 patients and 1720 control subjects.

Methods  Cases were sorted into 5 groups (erythema multiforme majus, Stevens-Johnson syndrome, Stevens-Johnson syndrome–toxic epidermal necrolysis overlap, toxic epidermal necrolysis, and unclassified erythema multiforme majus or Stevens-Johnson syndrome) by experts blinded as to exposure to drugs and other factors. Etiologic fractions for herpes and drugs obtained from case-control analyses were compared between these groups.

Results  Erythema multiforme majus significantly differed from Stevens-Johnson syndrome, overlap, and toxic epidermal necrolysis by occurrence in younger males, frequent recurrences, less fever, milder mucosal lesions, and lack of association with collagen vascular diseases, human immunodeficiency virus infection, or cancer. Recent or recurrent herpes was the principal risk factor for erythema multiforme majus (etiologic fractions of 29% and 17%, respectively) and had a role in Stevens-Johnson syndrome (etiologic fractions of 6% and 10%) but not in overlap cases or toxic epidermal necrolysis. Drugs had higher etiologic fractions for Stevens-Johnson syndrome, overlap, or toxic epidermal necrolysis (64%-66%) than for erythema multiforme majus (18%). Unclassified cases mostly behaved clinically like erythema multiforme.

Conclusions  This large prospective study confirmed that erythema multiforme majus differs from Stevens-Johnson syndrome and toxic epidermal necrolysis not only in severity but also in several demographic characteristics and causes.


From the Department of Biostatistics and Epidemiology, Institut Gustave-Roussy, Villejuif, France (Ms Auquier-Dunant); Dokumentationszentrum schwerer Hautreaktionen/Department of Dermatology, Albert-Ludwigs-Universität, Freiburg, Germany (Drs Mockenhaupt and Schröder); Gruppo Italiano Studi Epidemiologici in Dermatologia/Department of Dermatology, Università degli Studi di Milano, Bergamo, Italy (Dr Naldi); Grupo Português ELYS/Department of Dermatology and Immunology, Hospital S. João, Faculdade de Medicina, Porto, Portugal (Dr Correia); and Department of Dermatology, Hôpital Henri Mondor, Université Paris XII, Créteil, France (Dr Roujeau). A complete listing of the members of the Severe Cutaneous Adverse Reactions (SCAR) Study Group has been published previously (N Engl J Med. 1995;333:1606).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Medications as Risk Factors of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children: A Pooled Analysis
Levi et al.
Pediatrics 2009;123:e297-e304.
ABSTRACT | FULL TEXT  

Acute Skin Eruptions That Are Positive for Herpes Simplex Virus DNA Polymerase in Patients With Stem Cell Transplantation: A New Manifestation Within the Erythema Multiforme Reactive Dermatoses
Burnett et al.
Arch Dermatol 2008;144:902-907.
ABSTRACT | FULL TEXT  

Association of Fas Ligand gene polymorphism with Stevens-Johnson syndrome
Ueta et al.
Br. J. Ophthalmol. 2008;92:989-991.
ABSTRACT | FULL TEXT  

Erythema multiforme with tumour necrosis factor inhibitors: a class effect?
Kain et al.
Ann Rheum Dis 2008;67:899-900.
FULL TEXT  

Association of Combined IL-13/IL-4R Signaling Pathway Gene Polymorphism with Stevens-Johnson Syndrome Accompanied by Ocular Surface Complications
Ueta et al.
IOVS 2008;49:1809-1813.
ABSTRACT | FULL TEXT  

Cutaneous Reactions to Drugs in Children
Segal et al.
Pediatrics 2007;120:e1082-e1096.
ABSTRACT | FULL TEXT  

Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus
Paradela et al.
Lupus 2007;16:741-745.
ABSTRACT  

Cutaneous Adverse Reactions to Valdecoxib Distinct From Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Ziemer et al.
Arch Dermatol 2007;143:711-716.
ABSTRACT | FULL TEXT  

Colonic involvement in Stevens-Johnson syndrome.
Powell et al.
Postgrad. Med. J. 2006;82:e10-e10.
ABSTRACT | FULL TEXT  

SEVERE CUTANEOUS REACTIONS TO SULFADOXINE-PYRIMETHAMINE AND TRIMETHOPRIM-SULFAMETHOXAZOLE IN BLANTYRE DISTRICT, MALAWI.
GIMNIG et al.
Am J Trop Med Hyg 2006;74:738-743.
ABSTRACT | FULL TEXT  

Cell-Mediated Immunologic Mechanism and Severity of TEN
Faye et al.
Arch Dermatol 2005;141:775-776.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2002 American Medical Association. All Rights Reserved.